Universe · entity
BAKER BROS. ADVISORS LP
Institutional manager (13F) · CIK 1263508
13F holdings · as of 2026-03-31 · top 50 · reported portfolio $17.1B
| # | Issuer | Value | Shares |
|---|---|---|---|
| 1 | Incyte Corporation | $2.9B | 30,744,412 |
| 2 | BeOne Medicines Ltd. | $2.6B | 8,799,053 |
| 3 | Insmed Incorporated | $1.2B | 7,421,111 |
| 4 | Madrigal Pharmaceuticals, Inc. | $1.1B | 2,141,701 |
| 5 | ACADIA Pharmaceuticals Inc. | $955M | 42,896,690 |
| 6 | Revolution Medicines, Inc. | $929M | 9,555,357 |
| 7 | Celcuity Inc. | $904M | 7,915,792 |
| 8 | Kodiak Sciences Inc. | $759M | 19,919,186 |
| 9 | Kymera Therapeutics, Inc. | $721M | 8,657,242 |
| 10 | Summit Therapeutics Inc. | $690M | 36,391,063 |
| 11 | Praxis Precision Medicines, Inc. | $565M | 1,753,198 |
| 12 | Rhythm Pharmaceuticals, Inc. | $487M | 5,604,483 |
| 13 | Alkermes plc | $354M | 10,012,267 |
| 14 | GRAIL, Inc. | $208M | 4,028,614 |
| 15 | Edgewise Therapeutics, Inc. | $207M | 6,575,940 |
| 16 | Ionis Pharmaceuticals, Inc. | $154M | 2,047,727 |
| 17 | Kiniksa Pharmaceuticals International, plc | $136M | 2,826,246 |
| 18 | Immunovant, Inc. | $136M | 5,457,881 |
| 19 | Roivant Sciences Ltd. | $135M | 4,867,723 |
| 20 | IDEAYA Biosciences, Inc. | $131M | 3,946,515 |
| 21 | Arrowhead Pharmaceuticals, Inc. | $125M | 1,992,783 |
| 22 | Stoke Therapeutics, Inc. | $109M | 3,336,697 |
| 23 | Immatics N.V. | $107M | 10,916,693 |
| 24 | AbCellera Biologics Inc. | $106M | 30,275,938 |
| 25 | Abivax S.A. | $98M | 875,796 |
| 26 | Crinetics Pharmaceuticals, Inc. | $85M | 2,351,465 |
| 27 | Replimune Group, Inc. | $84M | 11,045,336 |
| 28 | Celcuity Inc. | $75M | 30,750,000 |
| 29 | Nurix Therapeutics, Inc. | $72M | 4,658,556 |
| 30 | Denali Therapeutics Inc. | $72M | 3,731,695 |
| 31 | Dianthus Therapeutics, Inc. | $72M | 852,164 |
| 32 | Monte Rosa Therapeutics, Inc. | $71M | 4,345,736 |
| 33 | Structure Therapeutics Inc. | $69M | 1,432,529 |
| 34 | Entrada Therapeutics, Inc. | $64M | 5,072,730 |
| 35 | Bicycle Therapeutics plc | $51M | 10,885,357 |
| 36 | Spyre Therapeutics, Inc. | $50M | 1,000,000 |
| 37 | Rapport Therapeutics, Inc. | $48M | 1,547,090 |
| 38 | Alumis Inc. | $44M | 2,012,500 |
| 39 | Mirum Pharmaceuticals, Inc. | $41M | 445,975 |
| 40 | Viridian Therapeutics, Inc. | $39M | 1,971,678 |
| 41 | Enliven Therapeutics, Inc. | $35M | 905,191 |
| 42 | Prelude Therapeutics Inc. | $35M | 10,123,824 |
| 43 | DBV Technologies S.A. | $31M | 1,461,425 |
| 44 | Design Therapeutics, Inc. | $28M | 2,585,978 |
| 45 | Centessa Pharmaceuticals plc | $27M | 670,751 |
| 46 | CytomX Therapeutics, Inc. | $23M | 4,975,826 |
| 47 | Jade Biosciences, Inc. | $23M | 1,641,137 |
| 48 | Disc Medicine, Inc. | $22M | 349,657 |
| 49 | Immunocore Holdings plc | $22M | 734,397 |
| 50 | Xenon Pharmaceuticals Inc. | $22M | 370,208 |
Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.